Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors. (October 2022) - Drilon, A.; Besse, B.; Camidge, D.R.; Ou, S.H.I.; Gadgeel, S.M.; Johnson, M.L.; Calles, A.; de Miguel, M.J.; Spira, A.I.; Felip, E.; Lopes, G.; van der Wekken, A.J.; et al.